+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global Drug Allergy Market Size was valued at USD 3.7 billion in 2022. The Drug Allergy market industry is projected to grow from USD 4.20 billion in 2023 to USD 6.80 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.40% during the forecast period (2023 - 2032). Along with the number of research and development initiatives, medicine approvals, and product launches, the prevalence of different forms of allergies is rising, these are the key market drivers enhancing the market growth
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Each year, millions of people throughout the world have allergy symptoms. The American College of Allergy, Asthma & Immunology estimates that over 50 million Americans experience allergic reactions. Allergies are the sixth most prevalent chronic illness in the United States, costing about $18 billion annually. In the United States, seasonal allergic rhinitis (hay fever) will be present in 81 million people in 2021, or around 26% of adults and 19% of children. 25.7% of people (one in five) experience seasonal allergies. Nearly 16 million (6.2%) American adults and 4 million (5.8%) American children suffer from food allergies. Shellfish, milk, and peanut allergies are the most frequent. 4.1 million children, or 5.6%, reported having food allergies in the previous 12 months. Around the world, up to 10% of people could have unfavorable drug reactions.
Additionally, allergies are a complex issue with numerous underlying causes that are becoming more prevalent in the industrialized world. In addition to urbanization, genetics, and climate change, they include the hygiene theory, dietary modifications, exposure to environmental toxins, vitamin D deficiency, obesity, and a lack of exposure to microbial variables. In conclusion, the rise of allergies in the industrialized world is probably due to a combination of genetic, environmental, and lifestyle factors.Thus, driving the Drug Allergy market revenue.
The global Drug Allergy market segmentation, based on type includes non-immunologic, Immunologic, and Others. With 38% of market sales (1.48 billion) coming from the beverage segment, the market was dominated by this sector. In affluent countries, the prevalence of food-induced anaphylaxis has increased alarmingly over the past few decades and is still rising, especially in children.
The global Drug Allergy market segmentation, based on treatment, includes corticosteroids, Withdrawal of the drug, Antihistamines, and Others. The category for treating anaphylaxis brought in the greatest money (47.4%). It improves respiration, decreases skin edema, and improves blood flow. Adrenaline starts working within a few minutes. Usually, the muscle of the thigh is where it is injected.
The global Drug Allergy market segmentation, based on diagnosis, includes Blood tests, Skin tests, Patch test, and Others. The category of skin tests produced the largest revenue (43.4%). In addition to helping patients prevent or treat allergies and find skin cancer early, they are also relatively quick, easy, and safe to perform.
The global Drug Allergy market segmentation, based on end users, includes Academic institutes, Medical research centers, Hospitals & clinics, and Others. A number of variables, including accurate diagnosis, a multidisciplinary approach, more awareness, standardization of testing, and clinical decision support systems, have led to an increase in the need for drug allergy testing in hospitals and clinics.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study. The North America Drug Allergy Market dominated this market in 2022 (45.80%). This is the situation as a result of a developed healthcare system, rising environmental pollution, and an increase in the use of immunotherapy to treat allergies. As a result of rising chronic respiratory diseases, government regulations, research and development programs, and emerging food allergies, the market for allergy therapy is also growing in North America. Further, In the North American area, the U.S. Drug Allergy market had the biggest market share, while the Canada Drug Allergy market had the quickest rate of expansion.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
The second-largest market share for Drug Allergy is in Europe. Rising medication allergy instances and loose regulatory practices in various sectors are to blame for this. Further, In the European region, the German Drug Allergy market had the biggest market share, and the U.K. Drug Allergy market had the quickest rate of growth.
The Asia-Pacific Drug Allergy Market is expected to grow at the fastest CAGR from 2023 to 2032. Asthma and rhinoconjunctivitis are more prevalent in industrialized countries and regions like Korea, Japan, Hong Kong, and Singapore, whereas they are less prevalent in less developed countries and regions. The frequency and patterns of penicillin allergy sensitization in the Asia-Pacific region remain largely unclear. Overall, it is projected that the need for allergy therapy, particularly pharmaceutical allergy, would continue to rise in the Asia Pacific region. Moreover, In the Asia-Pacific region, the Indian Drug Allergy market had the quickest rate of growth while China's Drug Allergy market had the greatest market share.
Leading industry companies are making significant R&D investments in order to diversify their product offerings, which will drive the Drug Allergy market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants are also engaging in a number of strategic actions to increase their global footprint. The Drug Allergy sector needs to provide affordable products if it wants to grow and thrive in a more competitive and challenging market environment.
One of the primary business strategies employed by manufacturers in the worldwide Drug Allergy industry to assist customers and expand the market sector is local manufacturing to reduce operational costs. Some of the biggest benefits to medicine have recently come from the Drug Allergy sector.Major players in the Drug Allergy market, including Bayer (US), HAL Allergy Group (the Netherlands), AstraZeneca (UK), MAGNA Pharmaceuticals, Inc. (US), Circassia (US), Stallergenes Greer (UK), Johnson & Johnson Services, Inc. (US), and Others, are attempting to increase market demand by investing in research and development operations.
German-based Bayer is a worldwide firm active in a number of sectors, including biotechnology, consumer healthcare, agricultural chemicals, and pharmaceuticals. In Barmen, Germany, in 1863, dye trader Friedrich Bayer and dyer Friedrich Weskott established Bayer. Before expanding into other industries, the company first made dyestuffs. Bayer is one of the largest pharmaceutical companies in the world. Some of Bayer's current business segments include pharmaceuticals, consumer health, crop science, and animal health. Among the various countries where Bayer has assets and operations are the United States, Canada, Mexico, Germany, the Netherlands, and Australia.
Johnson & Johnson Services, Inc. was founded in 1886 and is a branch of Johnson & Johnson, an American multinational corporation that manufactures pharmaceuticals, consumer packaged goods, and medical equipment. The business Johnson & Johnson Services, Inc. sells materials for human medical care. The company's headquarters are in Brunswick, New Jersey. Johnson & Johnson Services, Inc. is a division of Johnson & Johnson. Johnson & Johnson is the biggest and most diverse producer of medical goods in the world. The company has operations in 60 nations and exports its products to more than 175 countries. Johnson & Johnson Services, Inc. maintains personal data in databases and with international and domestic third-party service providers.
· Bayer (US)
· HAL Allergy Group (the Netherlands)
· AstraZeneca (UK)
· MAGNA Pharmaceuticals, Inc. (US)
· Circassia (US)
· Stallergenes Greer (UK)
· Johnson & Johnson Services, Inc. (US)
· Others
April 2021: The Food and Drug Administration (FDA) has authorized the use of a short ragweed pollen allergen extract in the treatment of patients between the ages of 5 and 65. It includes short ragweed pollen-induced allergic rhinitis.
· Nonimmunologic
· Immunologic
· Others
· Corticosteroids
· Withdrawal of the drug
· Antihistamines
· Treatment of anaphylaxis
· Others
· Blood tests
· Skin tests
· Patch test
· Others
· Academic institutes
· Medical research centers
· Hospitals & clinics
· Others
· North America
- U.S.
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
Report Scope
|
Report Attribute/Metric |
Details |
|
Market Size 2022 |
USD 3.7 Billion |
|
Market Size 2023 |
USD 4.20 Billion |
|
Market Size 2032 |
USD 6.80 Billion |
|
Compound Annual Growth Rate (CAGR) |
6.40% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USDBillion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Type, Treatment, Diagnosis, End Users, and Region |
|
Geographies Covered |
North America, Europe, AsiaPacific, and the Rest of the World |
|
Countries Covered |
The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
Bayer (US), HAL Allergy Group (the Netherlands), AstraZeneca (UK), MAGNA Pharmaceuticals, Inc. (US), Circassia (US), Stallergenes Greer (UK), Johnson & Johnson Services, Inc. (US), Others |
|
Key Market Opportunities |
Increase in the number of research and development activities |
|
Key Market Dynamics |
Rising drug approvals and launches, and an increase in the prevalence of various forms of allergies. |
The global Drug Allergy market size was valued at USD3.7Billion in 2022.
The global market is projected to grow at a CAGR of 6.40% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Bayer (US), HAL Allergy Group (the Netherlands), AstraZeneca (UK), MAGNA Pharmaceuticals, Inc. (US), Circassia (US), Stallergenes Greer (UK), Johnson & Johnson Services, Inc. (US), Others
The immunologic category dominated the market in 2022.
The treatment of anaphylaxishad the largest share in the global market.
Report Code :
RL65272
Published on :
Sep 2023
Request a Free Sample Report
Speak to Analyst